Kura Oncology (KURA) and its partner Kyowa Kirin said Thursday that updated clinical data from their phase 1a/1b trial of ziftomenib combined with standards of care showed that 92% of 71 response-evaluable patients with acute myeloid leukemia achieved a composite complete remission and 80% achieved a complete remission.
The study evaluated ziftomenib plus cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements.
The company said phase 3 studies further evaluating ziftomenib-based combination therapies are expected to start in H2.
Kura Oncology's shares were up 3.8% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.